» Articles » PMID: 31041566

Acute Adverse Events in Cardiac MR Imaging with Gadolinium-based Contrast Agents: Results from the European Society of Cardiovascular Radiology (ESCR) MRCT Registry in 72,839 Patients

Abstract

Objectives: To assess the incidence of acute adverse events (AAEs) in gadolinium-enhanced cardiac magnetic resonance (CMR) imaging.

Methods: Gadolinium-based contrast agent (GBCA)-enhanced CMR data from the multinational, multicenter European Society of Cardiovascular Radiology MRCT Registry was included. AAE severity was classified according to the American College of Radiology Manual on Contrast Media (mild, moderate, severe). Multivariable generalized linear mixed effect models were used to assess the likelihood of AAEs in various GBCA, adjusting for pharmacological stressor, main indications (i.e., suspected or known coronary artery disease or myocarditis), age, sex, and submitting center as a random effect.

Results: In the study population of 72,839 GBCA-enhanced CMRs, a total of 260 AAEs were reported (0.36%), with a minority of severe AAEs (n = 24, 0.033%). Allergic-like AAEs were less likely than physiologic AAEs (29% versus 71%). Patients without pharmacological stress imaging had a lower AAE rate (0.22%) compared to stress imaging (0.75%), with the highest AAE rates for regadenoson (2.95%). AAE rates also varied by GBCA subtype (overall p < 0.001). There was significant interaction between GBCA and pharmacological stressor (interaction p = 0.025), with AAE rates ranging between 0 and 10% for certain GBCA/stressor combinations. There was further marginal evidence that higher GBCA volume was associated with higher AAE incidence (OR = 1.02, p = 0.05).

Conclusion: GBCA-enhanced CMR imaging demonstrates low AAE rates comparable to those of other body regions. AAE likelihood correlates with GBCA subtype, pharmacological stressor, and imaging indication. Intravenous fluid administration in patients with cardiac impairment might contribute to these findings.

Key Points: • Acute adverse event rates in cardiac magnetic resonance (CMR) imaging with gadolinium-based contrast agents (GBCAs) are low (0.36%), especially for severe adverse events (0.033%). • Mild and moderate adverse events are more frequent during stress CMR imaging. • Physiologic AAEs are more common than allergic AAEs in CMR imaging.

Citing Articles

Impact of the COVID-19 pandemic on cardiac magnetic resonance imaging practices: insights from the MRCT registry.

Moser L, Lisi C, Gutberlet M, Boccalini S, Budde R, Francone M Eur Radiol. 2025; .

PMID: 39969555 DOI: 10.1007/s00330-025-11464-w.


Clinically Relevant Extracardiac Findings at Cardiac Imaging: Insights from the European MR/CT Registry.

Moser L, Gutberlet M, Vliegenthart R, Francone M, Budde R, Salgado R Radiol Cardiothorac Imaging. 2024; 6(5):e240117.

PMID: 39387666 PMC: 11540291. DOI: 10.1148/ryct.240117.


Review of Myocardial Ischemia, Scar, and Viability Estimation with Molecular Magnetic Resonance Imaging.

Sillanmaki S, Hartikainen S, Yla-Herttuala E Biomedicines. 2024; 12(8).

PMID: 39200146 PMC: 11351116. DOI: 10.3390/biomedicines12081681.


Competence of radiologists in cardiac CT and MR imaging in Europe: insights from the ESCR Registry.

Catapano F, Moser L, Francone M, Catalano C, Vliegenthart R, Budde R Eur Radiol. 2024; 34(9):5666-5677.

PMID: 38418626 PMC: 11364788. DOI: 10.1007/s00330-024-10644-4.


Myocardial Late Gadolinium Enhancement (LGE) in Cardiac Magnetic Resonance Imaging (CMR)-An Important Risk Marker for Cardiac Disease.

Meier C, Eisenblatter M, Gielen S J Cardiovasc Dev Dis. 2024; 11(2).

PMID: 38392254 PMC: 10888577. DOI: 10.3390/jcdd11020040.


References
1.
Pape M, Zacho H, Aaroe J, Jensen S, Petersen L . Safety and tolerability of regadenoson for myocardial perfusion imaging - first Danish experience. Scand Cardiovasc J. 2016; 50(3):180-6. DOI: 10.3109/14017431.2016.1163415. View

2.
Prenner B, Bukofzer S, Behm S, Feaheny K, McNutt B . A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol. 2012; 19(4):681-92. PMC: 3395344. DOI: 10.1007/s12350-012-9547-4. View

3.
Bruder O, Schneider S, Pilz G, van Rossum A, Schwitter J, Nothnagel D . 2015 Update on Acute Adverse Reactions to Gadolinium based Contrast Agents in Cardiovascular MR. Large Multi-National and Multi-Ethnical Population Experience With 37788 Patients From the EuroCMR Registry. J Cardiovasc Magn Reson. 2015; 17:58. PMC: 4501068. DOI: 10.1186/s12968-015-0168-3. View

4.
Prince M, Zhang H, Zou Z, Staron R, Brill P . Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol. 2011; 196(2):W138-43. DOI: 10.2214/AJR.10.4885. View

5.
Brink H, Dickerson J, Stephens J, Pickworth K . Comparison of the Safety of Adenosine and Regadenoson in Patients Undergoing Outpatient Cardiac Stress Testing. Pharmacotherapy. 2015; 35(12):1117-23. DOI: 10.1002/phar.1669. View